Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

Biotechnology

Healthcare
$5.30 -2.45%

-$0.27 today

Market cap
$430.84M
Beta
0.51
P/E (TTM)
-5.6
EPS (TTM)
-$1.92
52W Low $7.61High $18.31

Volume 1.67M

Average 1.21M

PHAT Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Phathom Pharmaceuticals, Inc.NASDAQ: PHAT

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $110K fell 37.9% year over year, behind the -25.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 14.1% from the prior quarter. Over 3 fiscal years it compounded at +0.7% a year.

Context

  • Depreciation & amortization amounted to 0.4% of revenue in FY2025, down 1.1 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -37.9% toward the trailing-twelve-month pace of -25.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$110K-14.1% QoQ
Last fiscal yearDec 2025
$633K-20.4% YoY
LTMMar 2026
$566K-25.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.9%——
1 year-20.4%——
3-year CAGR+0.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
633K USD
Year-over-year change
-20.4%
4-year CAGR
+5.0%

Depreciation & Amortization vs competitors

How PHAT compares with its peers on the latest reported figures

  • PHAT's LTM Mar 2026 depreciation & amortization of $566K is the lowest of the 2 companies compared; the peer median is $3.37M.
  • Its year-over-year change of -25.3% is the lowest of 2, against a peer median of +51.2%.
  • Depreciation & amortization amounts to 0.3% of revenue for PHAT, versus a peer median of 0.8%.
PHAT Competitors Peer median
Depreciation & Amortization for PHAT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARDXArdelyx, Inc.LTM Mar 2026$3.37M +51.2%+38.8%0.8%
PHATPhathom Pharmaceuticals, Inc.LTM Mar 2026$566K -25.3%+0.7%0.3%
Peer median (excluding PHAT) $3.37M+51.2%+38.8%0.8%

Competitors are the stored peer set for PHAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00682K55.25M175.11M
Cost of Revenue521K620K167K7.97M22.6M
Gross Profit(521K)(620K)515K47.28M152.51M
Gross Margin——75.5%85.6%87.1%
Research & Development72.34M71.44M49.9M34.08M32.78M
Selling, General & Admin62.22M100.38M117.93M290.66M279.72M
Operating Expenses134.56M171.82M167.83M324.75M312.5M
Depreciation & Amortization521K620K575K795K633K
EBITDA(136.57M)(169.8M)(159.05M)(261.52M)(152.5M)
EBITDA Margin——-23321.0%-473.3%-87.1%
Operating Income(135.08M)(172.44M)(167.31M)(277.47M)(159.99M)
Operating Margin——-24532.6%-502.2%-91.4%
Interest Income41K2.13M7.88M15.16M7.04M
Interest Expense6.79M27.31M41.97M72.01M68.12M
Other Income / Expenses(8.8M)(25.28M)(34.28M)(56.86M)(61.26M)
Income Before Tax(143.88M)(197.72M)(201.59M)(334.33M)(221.25M)
Pre-Tax Margin——-29558.9%-605.1%-126.3%
Income Tax Expense00000
Net Income(143.88M)(197.72M)(201.59M)(334.33M)(221.25M)
Net Margin——-29558.9%-605.1%-126.3%
EPS (Basic)(4.00)(5.70)(3.93)(5.29)(3.03)
EPS (Diluted)(4.00)(5.70)(3.93)(5.29)(3.03)
Weighted Avg Shares37M39.12M51.29M63.18M72.92M
Weighted Avg Shares (Diluted)37M39.12M51.29M63.18M72.92M

Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

Intrinsic Alpha fair value

Locked

Current Price

$5.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.